Compare Arqit Quantum Inc (ARQQ) vs Eli Lilly And Co (LLY) Price & Performance

ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.

Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.

Eli Lilly (LLY) trades at $1,188.58, down 2.33% over 24 hours, but maintains a strong technical bullish trend with support near $1,172. The company demonstrates exceptional fundamental strength, with 2025 revenue surging to $65.18B and net income reaching $20.64B, driven by robust demand for its obesity and diabetes drugs. Recent news highlights a $400B market cap surge over the past year and positive analyst coverage, though valuation multiples remain elevated.

Outlook remains positive given Lilly's dominance in high-growth therapeutic areas and consistent earnings beats, but risks include intense competition from Novo Nordisk and rich valuations. Wall Street consensus is strongly bullish with a $1,340 price target, suggesting 13% upside from current levels, supported by institutional confidence in long-term growth prospects.